Moran Rojansky
Analyst · BNP Paribas
Thank you, Amnon and thanks for joining the call, everyone. Before I begin, please be aware that all my comments on profitability will refer to non-GAAP measurement. The primary exclusion in Mobileye's non-GAAP numbers is amortization of intangible assets, which is mainly related to Intel’s acquisition of Mobileye in 2017. We also exclude stock-based compensation. Starting with Q1 results. They were closely aligned with the Q1 outlook we provided back in January. I'll provide a brief summary and then get into a bit more detail. The severe year-on-year decline in the key metrics was almost exclusively isolated to EyeQ volumes, which were impacted by the inventory correction. During the quarter, we delivered 3.5 million EyeQ chips. In addition to these new shipments, our customers use the significant amount of EyeQ inventory to satisfy the demand for products during the quarter. The approximately, 4.6 million units year-over-year decline, which converted at our high gross margin essentially counting for substantially all the reduction in gross profit. Our cost is nearly all variable. The fixed component is very minimal. The balance of the year-over-year decline in operating income was driven by some growth in operating expenses, but this was relatively minor and our operating expenses do not flex with revenue, as R&D spending is correlated with the execution of our advanced product strategy and is not impacted by short term fluctuations in revenue. Beyond the volume decline, we also saw some modest decline in EyeQ ASP and gross margin related to mix. SuperVision was pretty strong in the quarter. We delivered 39,000 units compared to 25,000 units in the year ago period. This was above expectation, but this was due to timing. We continue to see the first half deliveries totaling around 70,000 units, in line with our initial expectations, but with Q1 slightly higher than expected, Q2 slightly lower. SuperVision gross margin improved somehow in Q1, both sequentially and year-over-year. The more meaningful increase into the low 40 range is expected in Q2 as close to 100% of our volume will be with the new low-cost domain control. On an overall blended gross margin basis, the lower than normal percentage was related to the fact that SuperVision was around 20% of revenue in Q1 compared to an average of 6% in 2023 calendar year. While SuperVision volumes grew year-over-year, the mix of SuperVision was exaggerated by the temporary reduction in EyeQ volumes in the quarter, which will return to more normalized level in Q2 and even more so in the back half. Despite the operating loss, operating cash flow was modestly positive in the quarter. One item to note here is that our balance sheet inventory rose sequentially. This has nothing to do with inventory at the T1 customers. Our balance sheet inventory rose modestly due to lower shipments in the quarter and the need to maintain somehow steady purchasing of EyeQ chips over the course of the year. By the end of 2024, we would expect our balance sheet inventory to be consistent with the 2023 year-end figure. Looking ahead, we believe that the inventory consumption process is on track. At this point, the vast majority of Q2 volume is based on binding purchase orders from our customers. There is quite some level of uncertainty regarding timing of late quarter shipments, but we are comfortable in projecting approximately 7.4 million units, up more than 100% as compared to Q1. Based on our own analysis and information from our customers, we expect that inventory at our Tier 1 customers will be back around normal levels by the end of Q2. Please note that we may not continue to give as much specification on quarterly unit volume outlook, but given the unusual cadence of this year, we think it is worthwhile. We expect gross margin to move higher to around 67% and for operating expenses to continue to grow steadily on a sequential basis. Overall, our revenue and adjusted operating income expectation for Q2 are well aligned with the current analyst consensus. In terms of the full year guidance, it is unchanged from the outlook we provided on January 25. From a volume perspective, we are assuming 31 million to 33 million EyeQ shipments and 175,000 to 195,000 SuperVision in shipments in 2024. On the EyeQ side, the midpoint of our guidance implies around 21 million units in the back half. This is supported by regularly updated indication from our customers, which have been quite stable over the last couple of months. And it also appears to be reflective of the true level of demand in the back half of 2024 based on our own analysis of OEM production forecast. If we isolate average system price for the single chip EyeQ business, we expect it to be down slightly in 2024 on a year-over-year basis, consistent with our view in January. The modest weakening in vehicle mix that impacted us somehow in 2023 is expected to continue in 2024. This is compared to a very rich mix we saw in 2021 and 2022 due to overall automotive industry production constraints. Higher-priced chips for cloud-enhanced ADAS and other advanced programs are providing an offset, but we do not view this tailwind as very material in 2024 as cloud-enhanced ADAS volume are still not a meaningful portion of the total and the base of vehicles paying us annual REM-related license payments continue to build. On the SuperVision side, these volumes can be more difficult to precisely predict given that we are currently only on 5 models that are all in the EV space, which has been in a period of volatility. The increase in volumes in the second half of 2024 versus the first half of 2024 is supported by several factors, including: #1, the recent mid-cycle refresh of ZEEKR 001, which caused a significant uptick in demand. #2, incremental scaling of ZEEKR 001 volumes in Europe. #3, an additional version of the ZEEKR 009 with enhanced features. #4, the start of Polestar 4 deliveries in Europe and the U.S. in the second half. And #5, continued ramping of smart #1 in Volvo EM90 volumes. On a total company basis, we expect average system price to rise to approximately $55 in 2024 from $53 in 2023 based on SuperVision growth. We expect gross margin in the range of 67% to 68% range for the remainder of the year based on current expectations for the mix of SuperVision and EyeQ revenue. We continue to expect adjusted operating expenses to grow approximately 25% on a year-over-year basis as we execute on our advanced product portfolio in preparation for substantial numbers of SuperVision, Chauffeur and Drive product launches in upcoming years. And we continue to believe that our operating expenses in the near and long term should be structurally lower than we expected as of a year ago. And that OpEx percentage growth in '25 and beyond should be significantly lower than in 2024. Lastly, in terms of tax rate, we continue to assume a non-GAAP effective tax rate of 15% and 17% for 2024 in comparison to 11% in 2023. Thank you, and we will now take your questions.